A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis

Mira Ghaly, Corin Seelemann, Arezu Jahani-Asl

Research output: Contribution to journalComment/debate

4 Citations (Scopus)

Abstract

Chordoma is a rare primary bone cancer with limited treatment options. Surgical resection followed by radiotherapy has proven effective; however, when, in 30–40% of patients, tumours recur and metastasize, a high level of resistance to chemotherapies leaves these patients with a dearth of treatment options. Recent work published in the Journal of Pathology by Scheipl et al describing a focused compound drug screen highlights the significance of epidermal growth factor receptor (EGFR) signalling in chordoma, and shows potential for EGFR inhibitors as a way forward for developing an effective treatment for chordoma. Importantly, combining EGFR inhibitors with a MET inhibitor induces a synergistic effect on growth inhibition of resistant chordoma cells, highlighting the significance of combined EGFR and MET inhibitors as a potential avenue to defeat chemoresistance in chordoma patients.

Original languageEnglish (US)
Pages (from-to)381-383
Number of pages3
JournalJournal of Pathology
Volume240
Issue number4
DOIs
StatePublished - Dec 1 2016

Fingerprint

Chordoma
Epidermal Growth Factor Receptor
Bone Neoplasms
Radiotherapy
Therapeutics
Pathology
Drug Therapy
Growth
Pharmaceutical Preparations
Neoplasms

Keywords

  • EGFR inhibitors
  • MET inhibitors
  • chordoma
  • compound drug screen
  • crizotinib
  • met
  • sapitinib

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis. / Ghaly, Mira; Seelemann, Corin; Jahani-Asl, Arezu.

In: Journal of Pathology, Vol. 240, No. 4, 01.12.2016, p. 381-383.

Research output: Contribution to journalComment/debate

@article{f6215d97e298497db9853b3e51dfa9aa,
title = "A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis",
abstract = "Chordoma is a rare primary bone cancer with limited treatment options. Surgical resection followed by radiotherapy has proven effective; however, when, in 30–40{\%} of patients, tumours recur and metastasize, a high level of resistance to chemotherapies leaves these patients with a dearth of treatment options. Recent work published in the Journal of Pathology by Scheipl et al describing a focused compound drug screen highlights the significance of epidermal growth factor receptor (EGFR) signalling in chordoma, and shows potential for EGFR inhibitors as a way forward for developing an effective treatment for chordoma. Importantly, combining EGFR inhibitors with a MET inhibitor induces a synergistic effect on growth inhibition of resistant chordoma cells, highlighting the significance of combined EGFR and MET inhibitors as a potential avenue to defeat chemoresistance in chordoma patients.",
keywords = "EGFR inhibitors, MET inhibitors, chordoma, compound drug screen, crizotinib, met, sapitinib",
author = "Mira Ghaly and Corin Seelemann and Arezu Jahani-Asl",
year = "2016",
month = "12",
day = "1",
doi = "10.1002/path.4780",
language = "English (US)",
volume = "240",
pages = "381--383",
journal = "Journal of Pathology",
issn = "0022-3417",
publisher = "John Wiley and Sons Ltd",
number = "4",

}

TY - JOUR

T1 - A focused compound screen highlights the significance of epidermal growth factor receptor signalling in chordoma pathogenesis

AU - Ghaly, Mira

AU - Seelemann, Corin

AU - Jahani-Asl, Arezu

PY - 2016/12/1

Y1 - 2016/12/1

N2 - Chordoma is a rare primary bone cancer with limited treatment options. Surgical resection followed by radiotherapy has proven effective; however, when, in 30–40% of patients, tumours recur and metastasize, a high level of resistance to chemotherapies leaves these patients with a dearth of treatment options. Recent work published in the Journal of Pathology by Scheipl et al describing a focused compound drug screen highlights the significance of epidermal growth factor receptor (EGFR) signalling in chordoma, and shows potential for EGFR inhibitors as a way forward for developing an effective treatment for chordoma. Importantly, combining EGFR inhibitors with a MET inhibitor induces a synergistic effect on growth inhibition of resistant chordoma cells, highlighting the significance of combined EGFR and MET inhibitors as a potential avenue to defeat chemoresistance in chordoma patients.

AB - Chordoma is a rare primary bone cancer with limited treatment options. Surgical resection followed by radiotherapy has proven effective; however, when, in 30–40% of patients, tumours recur and metastasize, a high level of resistance to chemotherapies leaves these patients with a dearth of treatment options. Recent work published in the Journal of Pathology by Scheipl et al describing a focused compound drug screen highlights the significance of epidermal growth factor receptor (EGFR) signalling in chordoma, and shows potential for EGFR inhibitors as a way forward for developing an effective treatment for chordoma. Importantly, combining EGFR inhibitors with a MET inhibitor induces a synergistic effect on growth inhibition of resistant chordoma cells, highlighting the significance of combined EGFR and MET inhibitors as a potential avenue to defeat chemoresistance in chordoma patients.

KW - EGFR inhibitors

KW - MET inhibitors

KW - chordoma

KW - compound drug screen

KW - crizotinib

KW - met

KW - sapitinib

UR - http://www.scopus.com/inward/record.url?scp=84991810721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991810721&partnerID=8YFLogxK

U2 - 10.1002/path.4780

DO - 10.1002/path.4780

M3 - Comment/debate

C2 - 27538356

AN - SCOPUS:84991810721

VL - 240

SP - 381

EP - 383

JO - Journal of Pathology

JF - Journal of Pathology

SN - 0022-3417

IS - 4

ER -